{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089091","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.758693+00:00","generated_at":"2026-06-11T23:23:55.897711+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Century Therapeutics Q2 net loss $33.3M; cash $301M; CNTY-101 data expected by year end","bullets":["Net loss of $33.3M for Q2 2023 vs $31.0M in Q2 2022; net cash used in operations $48.5M in H1 2023.","Cash, equivalents, and investments $301.0M as of June 30, 2023; runway expected into 2026.","Phase 1 ELiPSE-1 trial of CNTY-101 ongoing; initial data from Schedule A expected by year end 2023.","Full year GAAP operating expense guidance $135M-$145M; includes $12M-$17M stock-based compensation.","Recorded $4.2M impairment charge for consolidation of two leased facilities in Philadelphia."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089091","json":"https://secwatch.observer/filing/0001104659-23-089091.json","markdown":"https://secwatch.observer/filing/0001104659-23-089091.md","text":"https://secwatch.observer/filing/0001104659-23-089091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923089091/0001104659-23-089091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923089091/tm2322816d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T23:23:55.897711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41c99939e6b204ccb3ae8473f4df5ee3d093ecf0","claim":"Century Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $33.3 million for the three months ended June 30, 2023. Guidance reaffirmed.","evidence_excerpt":"issued a press release announcing its financial results for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923089091/0001104659-23-089091-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $33.3 million for the three months ended June 30, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}